Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis
- 3 November 2024
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (1) , 103-110
Abstract
Background and Aims: Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable treatment option for selected patients. However, its safety profile in liver cirrhosis (LC) populations remains underexplored.Methods: This was an observational analysis of the National Inpatient Sample Database 2016–2020; we analyzed adult encounters undergoing CA for atrial fibrillation who had a concomitant diagnosis of LC. Using propensity scores, encounters were divided into two cohorts based on the presence or absence of LC and matched in a 1:1 fashion using LC as the dependent variable. In‐hospital mortality and postprocedure total complications were compared using regression models.Results: 93 830 procedures were identified for non‐LC patients and 960 involving LC patients; after propensity score matching, each cohort included 910 hospitalizations. The mean age in the LC‐matched cohort was 66.5 ± 9.1 years. In‐hospital mortality did not differ between the groups (aOR = 1.01; 95% CI [0.06–16.1]; p = .99). However, the LC cohort exhibited higher odds of total complications (aOR = 1.98; 95% CI [1.42–2.75]; p < .001). Length of stay (LOS) was comparable, but total costs were higher in the LC cohort: LOS was 2 days (95% CI [1–3]) in the LC group versus 3 days (95% CI [1–4]) (p < .11) and LC: $202,000 (95% CI [$142 000–$261 000]) versus non‐LC: $189 000, (95% CI [$153 000–$222 000]) (p < .0001).Conclusion: In this national analysis of patients undergoing CA for AF, those with LC had similar in‐hospital mortality, postprocedure complications, and LOS compared to noncirrhotic patients. Furthermore, longitudinal studies are needed to assess the safety profile of CA in this subpopulation.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial FibrillationJACC, 2023
- Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam studyJournal of Hepatology, 2022
- Atrial FibrillationNew England Journal of Medicine, 2021
- Atrial fibrillation ablation strategies and technologies: past, present, and futureClinical Research in Cardiology, 2020
- Risk of Mortality Following Catheter Ablation of Atrial FibrillationJACC, 2019
- Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver DiseaseJACC, 2019
- Adherence to Methodological Standards in Research Using the National Inpatient SampleJAMA, 2017
- Assessment of Bleeding Risk in Patients with CirrhosisCurrent Hepatology Reports, 2015
- Catheter ablation of postinfarction ventricular tachycardia: Ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United StatesHeart Rhythm, 2014
- Catheter ablation of atrial fibrillation: an updateEuropean Heart Journal, 2014